These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 37111318)

  • 1. A Treat-and-Extend Regimen of Intravitreal Brolucizumab for Exudative Age-Related Macular Degeneration Refractory to Aflibercept: A 12-Month Result.
    Kikushima W; Sakurada Y; Fukuda Y; Matsubara M; Kotoda Y; Sugiyama A; Kashiwagi K
    Pharmaceuticals (Basel); 2023 Apr; 16(4):. PubMed ID: 37111318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Switching from aflibercept to brolucizumab for the treatment of refractory neovascular age-related macular degeneration.
    Ota H; Takeuchi J; Nakano Y; Horiguchi E; Taki Y; Ito Y; Terasaki H; Nishiguchi KM; Kataoka K
    Jpn J Ophthalmol; 2022 May; 66(3):278-284. PubMed ID: 35233693
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Switching to brolucizumab from aflibercept in age-related macular degeneration with type 1 macular neovascularization and polypoidal choroidal vasculopathy: an 18-month follow-up study.
    Ueda-Consolvo T; Tanigichi A; Numata A; Oiwake T; Nakamura T; Ishida M; Yanagisawa S; Hayashi A
    Graefes Arch Clin Exp Ophthalmol; 2023 Feb; 261(2):345-352. PubMed ID: 35947181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Short-term outcomes of switching to brolucizumab in japanese patients with neovascular age-related macular degeneration.
    Kitajima Y; Maruyama-Inoue M; Ikeda S; Ito A; Inoue T; Yanagi Y; Kadonosono K
    Jpn J Ophthalmol; 2022 Nov; 66(6):511-517. PubMed ID: 36149566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aflibercept for exudative AMD with persistent fluid on ranibizumab and/or bevacizumab.
    Cho H; Shah CP; Weber M; Heier JS
    Br J Ophthalmol; 2013 Aug; 97(8):1032-5. PubMed ID: 23766432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of Outcomes between 3 Monthly Brolucizumab and Aflibercept Injections for Polypoidal Choroidal Vasculopathy.
    Fukuda Y; Sakurada Y; Matsubara M; Hasebe Y; Sugiyama A; Kikushima W; Kashiwagi K
    Biomedicines; 2021 Sep; 9(9):. PubMed ID: 34572350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Switching from a Fixed Monthly Aflibercept Regimen to Bi-Monthly Brolucizumab in Refractory Cases of Neovascular Age-Related Macular Degeneration.
    Kim M; Kang JE; Park YG
    J Clin Med; 2024 Jun; 13(12):. PubMed ID: 38929964
    [No Abstract]   [Full Text] [Related]  

  • 8. Subfoveal choroidal thickness in polypoidal choroidal vasculopathy after switching to intravitreal aflibercept injection.
    Saito M; Kano M; Itagaki K; Ise S; Imaizumi K; Sekiryu T
    Jpn J Ophthalmol; 2016 Jan; 60(1):35-41. PubMed ID: 26350229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Effect of a Loading Dose Regimen in the Switch to Brolucizumab for Patients with Aflibercept-Resistant nAMD.
    Kamao H; Mitsui E; Date Y; Goto K; Mizukawa K; Miki A
    J Ophthalmol; 2024; 2024():3673930. PubMed ID: 38322501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of intravitreal aflibercept in Japanese patients with exudative age-related macular degeneration.
    Saito M; Kano M; Itagaki K; Sekiryu T
    Jpn J Ophthalmol; 2017 Jan; 61(1):74-83. PubMed ID: 27660164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective clinical trial of Intravitreal aflibercept treatment for PolypoIdal choroidal vasculopathy with hemorrhage or exudation (EPIC study): 6 month results.
    Kokame GT; Lai JC; Wee R; Yanagihara R; Shantha JG; Ayabe J; Hirai K
    BMC Ophthalmol; 2016 Jul; 16():127. PubMed ID: 27465105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-World Experience Using Intravitreal Brolucizumab Alone or in Combination with Aflibercept in the Management of Neovascular Age-Related Macular Degeneration.
    Mehta N; Fong RD; Wilson M; Moussa K; Emami-Naeini P; Moshiri A; Yiu G; Park SS
    Clin Ophthalmol; 2023; 17():657-665. PubMed ID: 36880020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short-Term Morphofunctional Changes in Previously Treated Neovascular AMD Eyes Switched to Brolucizumab.
    Viggiano P; Grassi MO; Boscia G; Pignataro M; Petruzzella G; Borrelli E; Molfetta T; Alessio G; Boscia F
    J Clin Med; 2022 Sep; 11(19):. PubMed ID: 36233385
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brolucizumab Versus Aflibercept in Participants with Neovascular Age-Related Macular Degeneration: A Randomized Trial.
    Dugel PU; Jaffe GJ; Sallstig P; Warburton J; Weichselberger A; Wieland M; Singerman L
    Ophthalmology; 2017 Sep; 124(9):1296-1304. PubMed ID: 28551167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. One-year results of treat-and-extend regimen with intravitreal brolucizumab for treatment-naïve neovascular age-related macular degeneration with type 1 macular neovascularization.
    Matsumoto H; Hoshino J; Mukai R; Nakamura K; Akiyama H
    Sci Rep; 2022 May; 12(1):8195. PubMed ID: 35581196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Switching to intravitreal aflibercept injection for polypoidal choroidal vasculopathy refractory to ranibizumab.
    Saito M; Kano M; Itagaki K; Oguchi Y; Sekiryu T
    Retina; 2014 Nov; 34(11):2192-201. PubMed ID: 25077530
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-World Experience with Brolucizumab Compared to Aflibercept in Treatment-Naïve and Therapy-Refractory Patients with Diabetic Macular Edema.
    Rübsam A; Hössl L; Rau S; Böker A; Zeitz O; Joussen AM
    J Clin Med; 2024 Mar; 13(6):. PubMed ID: 38542043
    [No Abstract]   [Full Text] [Related]  

  • 18. Two-Year Outcomes of Treat-and-Extend Intravitreal Aflibercept for Exudative Age-Related Macular Degeneration: A Prospective Study.
    Maruko I; Ogasawara M; Yamamoto A; Itagaki K; Hasegawa T; Arakawa H; Nakayama M; Koizumi H; Okada AA; Sekiryu T; Iida T
    Ophthalmol Retina; 2020 Aug; 4(8):767-776. PubMed ID: 32417356
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two-year functional and anatomical results after converting treatment resistant eyes with exudative age-related macular degeneration to aflibercept in accordance with a treat and extend protocol.
    Jørstad ØK; Faber RT; Moe MC
    Acta Ophthalmol; 2017 Aug; 95(5):460-463. PubMed ID: 28556485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subfoveal choroidal thickness after brolucizumab therapy for neovascular age-related macular degeneration: a short-term multicenter study.
    Tamashiro T; Tanaka K; Itagaki K; Nakayama M; Maruko I; Wakugawa S; Terao N; Onoe H; Wakatsuki Y; Ogasawara M; Sugano Y; Yamamoto A; Kataoka K; Izumi T; Kawai M; Mori R; Sekiryu T; Okada AA; Iida T; Koizumi H;
    Graefes Arch Clin Exp Ophthalmol; 2022 Jun; 260(6):1857-1865. PubMed ID: 35034215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.